Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I bioavailability study of PA 10040, POZEN's proprietary combination of aspirin (100mg)/omeprazole (40mg), versus a European Union reference listed enteric-coated (EC) aspirin (100mg)

Next Previous
Trial Profile

Phase I bioavailability study of PA 10040, POZEN's proprietary combination of aspirin (100mg)/omeprazole (40mg), versus a European Union reference listed enteric-coated (EC) aspirin (100mg)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced ulcer
  • Focus Pharmacokinetics

Most Recent Events

  • 08 Aug 2013 New trial record
  • 06 Aug 2013 Status changed from not yet recruiting to completed, based on results reported in a POZEN media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top